维奈克拉与吉瑞替尼在FLT3野生型高危急性髓系白血病中通过抑制MCL-1协同作用
研究通过高通量药物筛选在31例高危急性髓系白血病原代样本中测试64种抗白血病药物,发现吉瑞替尼与维奈克拉在FLT3野生型AML中协同性最高;该组合增加凋亡、降低活力,机制涉及AXL/FLT3抑制后ERK/GSK3B磷酸化下降及MCL-1降解。
要点
- 高通量筛选31例高危AML原代样本中64种药物,吉瑞替尼与维奈克拉协同性最高。
- 联合用药在维奈克拉-阿扎胞苷耐药细胞系及原代样本中仍有活性。
- 机制为AXL/FLT3抑制降低ERK/GSK3B磷酸化并促进MCL-1降解。
核心结论
- 研究结果提示,联合抑制FLT3/AXL可通过诱导MCL-1降解增强维奈克拉在FLT3野生型AML中的应答。
研究设计与样本
- 在31例高危AML原代样本中对64种抗白血病药物进行高通量药物筛选,含或不含维奈克拉。
- 研究类型原文未明确报告。
主要发现
- 吉瑞替尼在FLT3野生型AML中与维奈克拉协同性最高。
- 吉瑞替尼与维奈克拉联合增加凋亡、降低活力,并在维奈克拉-阿扎胞苷耐药细胞系及原代患者样本中有活性。
- 对当前维奈克拉-阿扎胞苷组合体外低应答的标本中,蛋白质组学显示FLT3野生型信号增强。
- 维奈克拉联合吉瑞替尼通过AXL和FLT3联合抑制降低ERK和GSK3B磷酸化,随后抑制抗凋亡蛋白MCL-1。
- MCL-1下调伴随MCL-1丝氨酸159磷酸化增加、苏氨酸161磷酸化降低及蛋白酶体降解。
临床怎么用
- 作者认为,维奈克拉-吉瑞替尼组合值得在高危FLT3野生型AML患者中作为潜在有效方案进行检测。
- 4例FLT3野生型AML患者在维奈克拉-阿扎胞苷治疗下出现难治性疾病后,接受标签外维奈克拉-吉瑞替尼治疗,白血病负荷降低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BCL-2 inhibition has been shown to be effective in acute myeloid leukemia (AML) in combination with hypomethylating agents or low-dose cytarabine. However, resistance and relapse represent major clinical challenges. Therefore, there is an unmet need to overcome resistance to current venetoclax-based strategies. We performed high-throughput drug screening to identify effective combination partners for venetoclax in AML. Overall, 64 antileukemic drugs were screened in 31 primary high-risk AML samples with or without venetoclax. Gilteritinib exhibited the highest synergy with venetoclax in FLT3 wild-type AML. The combination of gilteritinib and venetoclax increased apoptosis, reduced viability, and was active in venetoclax-azacitidine-resistant cell lines and primary patient samples. Proteomics revealed increased FLT3 wild-type signaling in specimens with low in vitro response to the currently used venetoclax-azacitidine combination. Mechanistically, venetoclax with gilteritinib decreased phosphorylation of ERK and GSK3B via combined AXL and FLT3 inhibition with subsequent suppression of the antiapoptotic protein MCL-1. MCL-1 downregulation was associated with increased MCL-1 phosphorylation of serine 159, decreased phosphorylation of threonine 161, and proteasomal degradation. Gilteritinib and venetoclax were active in an FLT3 wild-type AML patient-derived xenograft model with TP53 mutation and reduced leukemic burden in 4 patients with FLT3 wild-type AML receiving venetoclax-gilteritinib off label after developing refractory disease under venetoclax-azacitidine. In summary, our results suggest that combined inhibition of FLT3/AXL potentiates venetoclax response in FLT3 wild-type AML by inducing MCL-1 degradation. Therefore, the venetoclax-gilteritinib combination merits testing as a potentially active regimen in patients with high-risk FLT3 wild-type AML.
引用
- Janssen M, Schmidt C, Bruch PM, et al. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. Blood. 2022. PMID: 35857899. doi:10.1182/blood.2021014241
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。